Shenzhen Hepalink Pharmaceutical Group Future Growth
Future criteria checks 3/6
Shenzhen Hepalink Pharmaceutical Group is forecast to grow earnings and revenue by 65.9% and 6.5% per annum respectively. EPS is expected to grow by 65.9% per annum. Return on equity is forecast to be 6.1% in 3 years.
Key information
65.9%
Earnings growth rate
65.9%
EPS growth rate
Pharmaceuticals earnings growth | 18.8% |
Revenue growth rate | 6.5% |
Future return on equity | 6.1% |
Analyst coverage | Low |
Last updated | 15 Jul 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 6,545 | 836 | N/A | N/A | 1 |
12/31/2025 | 6,131 | 779 | N/A | N/A | 1 |
12/31/2024 | 5,673 | 644 | N/A | N/A | 1 |
3/31/2024 | 5,518 | -695 | 1,044 | 1,493 | N/A |
12/31/2023 | 5,446 | -783 | -47 | 398 | N/A |
9/30/2023 | 5,827 | 218 | -606 | -271 | N/A |
6/30/2023 | 6,114 | 340 | -1,314 | -1,059 | N/A |
3/31/2023 | 6,550 | 559 | -1,212 | -969 | N/A |
1/1/2023 | 7,159 | 727 | -979 | -757 | N/A |
9/30/2022 | 7,129 | 432 | -1,060 | -849 | N/A |
6/30/2022 | 7,010 | 414 | -722 | -513 | N/A |
3/31/2022 | 7,008 | 332 | -611 | -428 | N/A |
1/1/2022 | 6,365 | 241 | -200 | -7 | N/A |
9/30/2021 | 6,421 | 777 | 96 | 290 | N/A |
6/30/2021 | 5,786 | 781 | 359 | 548 | N/A |
3/31/2021 | 5,198 | 912 | 484 | 675 | N/A |
12/31/2020 | 5,332 | 1,024 | -175 | 37 | N/A |
9/30/2020 | 5,028 | 1,097 | -456 | -206 | N/A |
6/30/2020 | 5,155 | 1,094 | -603 | -290 | N/A |
3/31/2020 | 5,004 | 808 | -634 | -307 | N/A |
12/31/2019 | 4,625 | 1,059 | -590 | -228 | N/A |
9/30/2019 | 4,622 | 812 | -483 | -9 | N/A |
6/30/2019 | 4,736 | 894 | -184 | 304 | N/A |
3/31/2019 | 4,879 | 1,030 | 69 | 575 | N/A |
12/31/2018 | 4,815 | 591 | 101 | 636 | N/A |
9/30/2018 | 4,307 | 565 | -5 | 472 | N/A |
6/30/2018 | 3,905 | 437 | -742 | -164 | N/A |
3/31/2018 | 3,347 | 278 | -1,155 | -500 | N/A |
12/31/2017 | 2,843 | 197 | N/A | -486 | N/A |
9/30/2017 | 2,486 | 176 | N/A | -404 | N/A |
6/30/2017 | 2,218 | 140 | N/A | 50 | N/A |
3/31/2017 | 2,045 | 189 | N/A | 226 | N/A |
12/31/2016 | 2,261 | 397 | N/A | 346 | N/A |
9/30/2016 | 2,318 | 466 | N/A | 436 | N/A |
6/30/2016 | 2,279 | 566 | N/A | 603 | N/A |
3/31/2016 | 2,223 | 590 | N/A | 694 | N/A |
12/31/2015 | 2,292 | 580 | N/A | 894 | N/A |
9/30/2015 | 2,141 | 532 | N/A | 936 | N/A |
6/30/2015 | 2,251 | 503 | N/A | 1,128 | N/A |
3/31/2015 | 2,387 | 453 | N/A | 1,029 | N/A |
12/31/2014 | 1,959 | 338 | N/A | 913 | N/A |
9/30/2014 | 1,718 | 250 | N/A | 726 | N/A |
6/30/2014 | 1,477 | 177 | N/A | 475 | N/A |
3/31/2014 | 1,375 | 249 | N/A | 513 | N/A |
12/31/2013 | 1,513 | 317 | N/A | 421 | N/A |
9/30/2013 | 1,652 | 436 | N/A | 303 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002399 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 002399 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 002399 is expected to become profitable in the next 3 years.
Revenue vs Market: 002399's revenue (6.5% per year) is forecast to grow slower than the CN market (13.4% per year).
High Growth Revenue: 002399's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002399's Return on Equity is forecast to be low in 3 years time (6.1%).